Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT04474301
- Status
- Recruiting
Conditions
- COVID-19 Infection
- Melanoma
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Survey Administration — OTHERComplete survey
Study Details
The primary purpose of this study is to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted multiple domains of health-related quality of life and other areas such as COVID-19 specific psychological distress, and disruptions to health care, finances and social interactions. We will also evaluate the extent to which resiliency factors such as social support, perceived benefits under times of stress, and ability to manage stress may buffer associations between COVID-19 experiences and HRQoL. To meet these objectives, we have developed a 10-minute questionnaire that taps into these areas and is based on prior work addressing concerns of other pandemics or national crises. Participants will have previously consented to protocol PA15-0336 and have provided prior lifestyle data. This will allow us to connect the COVID-19 survey data with prior existing data.
Key Dates
- Start date
- Jun 11, 2020
- Status verified
- Apr 2026
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2026
Study Design
- Enrollment
- 1,152 participants (estimated)
Arms
- Arm: Observational (survey administration)Patients complete a survey over 10 minutes.
Primary Outcome Measure
Experiences during the COVID-19 pandemic [ Time Frame: Survey completion Up to 2 months ]
Central Contacts
- Lorenzo Cohen(713) 745-4260
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | Lorenzo Cohen Lorenzo Cohen (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
Related Studies
- Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy ProgramRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- Dabrafenib and/or Trametinib Rollover StudyPHASE4 · Recruiting · Novartis Pharmaceuticals · Scottsdale, Arizona
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama